Supplementary Table 1 Meta-analysis of the *NFKB1* -94ins/del ATTG promoter polymorphism and cancer risk among the studies which did not deviated from HWE

| Variable	n [a]	Cases / Controls	ins/ins versus del/del		ins/del versus del/del		ins/ins + ins/del vs. del/del (dominant)		ins/ins vs. ins/del + del/del (recessive)		ins allele vs. del allele	
			OR (95% CI)	I^2 (%)	OR (95% CI)	I^2 (%)	OR (95% CI)	I^2 (%)	OR (95% CI)	I^2 (%)	OR (95% CI)	I^2 (%)
Total	15	3968/6473	**1.65 (1.17–2.32)** [b]	86.2	**1.28 (1.03–1.60)** [b]	70.5	**1.41 (1.09–1.83)** [b]	81.2	**1.33 (1.08–1.63)** [b]	80.7	**1.26 (1.07–1.49)** [b]	86.3
Cancer types												
Bladder cancer	3	1058/1175	1.07 (0.45–2.53) [b]	90.1	1.00 (0.46–2.18) [b]	88.8	1.04 (0.46–2.33) [b]	90.7	1.04 (0.73–1.48) [b]	72.7	1.03 (0.70–1.51) [b]	89.0
Ovarian Cancer	2	366/444	**2.57 (1.66–3.98)**	0	**1.88 (1.23–2.89)**	0	**2.17 (1.45–3.25)**	0	**1.59 (1.19–2.11)**	0	**1.55 (1.27–1.90)**	0
Oral Cancer	2	674/721	**2.10 (1.54–2.87)**	33.0	**1.42 (1.10–1.83)**	0	**1.59 (1.25–2.03)**	3.9	**1.67 (1.29–2.17)**	0	**1.43 (1.23–1.66)**	6.9
Prostate Cancer	2	451/477	**1.59 (1.09–2.33)**	23.0	1.28 (0.89–1.84)	28.6	1.40 (1.00–1.98)	35.8	**1.33 (1.01–1.74)**	0	**1.26 (1.05–1.52)**	0
Other Cancers	6	1419/3656	1.66 (0.90–3.06) [b]	89.0	1.19 (0.99–1.43)	40.4	1.39 (0.95–2.04) [b]	77.6	1.35 (0.88–2.08) [b]	89.1	**1.26 (0.93–1.71)** [b]	90.0
Ethnicities												
Asian	11	2686/3380	**2.05 (1.34–3.14)** [b]	85.6	**1.40 (1.03–1.91)** [b]	77.1	**1.62 (1.15–2.29)** [b]	83.7	**1.56 (1.26–1.92)** [b]	68.8	**1.41 (1.16–1.71)** [b]	83.9
Caucasian	4	1282/3093	0.93 (0.65–1.32) [b]	64.7	1.04 (0.85–1.27)	0	0.97 (0.81–1.17)	33.8	0.88 (0.68–1.14) [b]	68.6	0.94 (0.78–1.13) [b]	70.2

[a] Number of comparisons
[b] Random effects estimate

Supplementary Table 2 Egger's linear regression test to measure the funnel plot asymmetric

Comparisons	ins/ins versus del/del		ins/del versus del/del		ins/ins + ins/del vs. del/del		ins/ins vs. ins/del + del/del		ins allele vs. del allele	
	A (95% CI)	*P* value	A (95% CI)	*P* value	A (95% CI)	*P* value	A (95% CI)	*P* value	A (95% CI)	*P* value
Total	7.06 (3.04–11.1)	0.002	4.08 (1.90–6.25)	0.001	5.27 (2.39–8.16)	0.001	4.66 (1.24–8.08)	0.010	5.48 (1.94–9.02)	0.004
Cancer types										
Bladder cancer	9.96 (-42.5–62.4)	0.250	8.01 (3.76–12.3)	0.027	9.14 (-12.6–30.9)	0.118	6.57 (-59.1–72.2)	0.424	10.0 (-38.2–58.2)	0.231
Colorectal Cancer	11.4 (-7.80–30.5)	0.125	-6.03 (-21.7–9.62)	0.239	0.83 (-32.2–33.8)	0.924	8.66 (-7.39–24.7)	0.146	10.1 (-2.77–23.0)	0.078
Ovarian Cancer	-	-	-	-	-	-	-	-	-	-
Oral Cancer	-	-	-	-	-	-	-	-	-	-
Prostate Cancer	-	-	-	-	-	-	-	-	-	-
Other Cancers	6.85 (0.89–12.8)	0.031	3.80 (0.80–6.81)	0.021	4.97 (1.05–8.89)	0.021	4.49 (-0.93–9.91)	0.089	4.66 (-0.23–9.55)	0.058
Ethnicities										
Asian	7.92 (3.06–12.8)	0.004	4.56 (1.44–7.70)	0.008	6.02 (2.09–9.95)	0.006	4.81 (1.59–8.03)	0.007	5.54 (1.54–9.54)	0.011
Caucasian	4.67 (0.36–8.99)	0.039	3.11 (-0.04–6.27)	0.052	3.36 (-5.10–11.8)	0.354	3.91 (1.28–6.55)	0.012	4.47 (-0.66–9.60)	0.075

A: Y axle intercept

Study ID		OR (95% CI)	% Weight
Lin [13] (2006)		1.26 (0.96, 1.66)	6.50
Riemann K [14] (2007)		1.02 (0.80, 1.31)	6.74
Lo [16] (2008)		1.80 (1.29, 2.51)	5.98
Zhang [17] (2009)		1.46 (1.03, 2.08)	5.80
Zhou [19] (2009)		1.45 (1.07, 1.96)	6.26
Tang [20] (2009)		1.46 (1.11, 1.93)	6.50
Andersen [21] (2010)		0.79 (0.66, 0.94)	7.26
Zhou [22] (2010)		1.49 (1.17, 1.91)	6.74
Fan [23] (2011)		1.52 (1.14, 2.03)	6.36
Lin [24] (2012)		1.50 (1.26, 1.80)	7.26
Vangsted [25] (2012)		0.85 (0.72, 1.01)	7.31
Huo [26] (2013)		1.58 (1.19, 2.10)	6.40
Cheng [27] (2013)		1.70 (1.30, 2.23)	6.54
Kopp [29] (2013)		1.20 (0.96, 1.49)	6.96
Li [12] (2013)		0.75 (0.64, 0.88)	7.39
Overall (I-squared = 86.3%, p = 0.000)		1.26 (1.07, 1.49)	100.00

NOTE: Weights are from random effects analysis

.399   1   2.51

Supplementary Figure 1. Forest plot of cancer risk associated with NFKB1 promoter -94ins/del ATTG polymorphism (for Insertion allele vs. Deletion allele) among the studies which did not deviated from HWE